PROS1 and benign prostatic hyperplasia: In a validation set, CEs not only potently distinguished PCa from normal tissue, but it also discriminated PCa from benign prostatic hyperplasia (BPH) superior to PSA, suggesting CE, particularly, cholesteryl oleate, as a biomarker for PCa detection (199).